227 related articles for article (PubMed ID: 19077094)
1. Complete remission of psoriasis following bevacizumab therapy for colon cancer.
Akman A; Yilmaz E; Mutlu H; Ozdogan M
Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094
[TBL] [Abstract][Full Text] [Related]
2. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
3. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
[TBL] [Abstract][Full Text] [Related]
4. [Anti-VEGF therapy with bevacizumab in breast cancer].
Tóth J; Gonda A; Szántó J
Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
[TBL] [Abstract][Full Text] [Related]
5. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells.
Calvani M; Trisciuoglio D; Bergamaschi C; Shoemaker RH; Melillo G
Cancer Res; 2008 Jan; 68(1):285-91. PubMed ID: 18172321
[TBL] [Abstract][Full Text] [Related]
6. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
8. Caution in adding bevacizumab in the adjuvant treatment of breast cancer.
Ziogas D; Roukos D
Ann Surg Oncol; 2010 Feb; 17(2):653-4; author reply 655-6. PubMed ID: 19888632
[No Abstract] [Full Text] [Related]
9. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
Canavese M; Altruda F; Ruzicka T; Schauber J
J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease.
Coriat R; Mir O; Leblanc S; Ropert S; Brezault C; Chaussade S; Goldwasser F
Inflamm Bowel Dis; 2011 Jul; 17(7):1632. PubMed ID: 21674721
[No Abstract] [Full Text] [Related]
11. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
12. Investigational VEGF antagonists for psoriasis.
Crawshaw AA; Griffiths CE; Young HS
Expert Opin Investig Drugs; 2012 Jan; 21(1):33-43. PubMed ID: 22088218
[TBL] [Abstract][Full Text] [Related]
13. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.
Wada J; Suzuki H; Fuchino R; Yamasaki A; Nagai S; Yanai K; Koga K; Nakamura M; Tanaka M; Morisaki T; Katano M
Anticancer Res; 2009 Mar; 29(3):881-8. PubMed ID: 19414323
[TBL] [Abstract][Full Text] [Related]
14. Suppression of melanoma-associated neoangiogenesis by bevacizumab.
Jaissle GB; Ulmer A; Henke-Fahle S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
Arch Dermatol; 2008 Apr; 144(4):525-7. PubMed ID: 18427047
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor inhibitors in colon cancer.
Díaz-Rubio E
Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
19. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Ferrara N; Hillan KJ; Gerber HP; Novotny W
Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
[No Abstract] [Full Text] [Related]
20. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
